PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Gout: Disease overview PART 06: Pipeline portfolio PART 07: Market landscape • Market overview • Five forces analysis PART 08: Key buying criteria PART 09: Market segmentation by drug class • NSAIDs • Corticosteroids • Colchicine • Urate-lowering agents PART 10: Market segmentation by type of disease PART 11: Geographical segmentation • Gout therapeutics market in Americas • Gout therapeutics market in EMEA • Gout therapeutics market in APAC • Market overview PART 12: Market drivers • Introduction of novel urate-lowering agents • Technological advancements in medical imaging • Popularity of off-label and OTC drugs PART 13: Impact of drivers PART 14: Market challenges • Low physician and patient awareness • Heavy dependency on generic drugs • Use of CAM for treatment of gout PART 15: Impact of drivers and challenges PART 16: Market trends • Focus on regenerative medicines • High growth potential of biologics • Preference for combination therapies PART 17: Vendor landscape • Competitive scenario • Other prominent vendors PART 18: Key vendor analysis • AstraZeneca • Horizon Pharma • Takeda Pharmaceuticals PART 19: Appendix • List of abbreviations PART 20: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Global gout therapeutics market overview Exhibit 03: Stages of gout Exhibit 04: Mechanism of gout Exhibit 05: Gout: overview Exhibit 06: Treatment algorithm for gout Exhibit 07: Pipeline analysis of major companies for global gout therapeutics market Exhibit 08: Share of pipeline molecules in global gout therapeutics market Exhibit 09: Few pipeline candidates under development in global gout therapeutics market: Exhibit 10: Market snapshot: Global gout therapeutics market Exhibit 11: Global statistics for gout in 2015 Exhibit 12: Correlation between serum uric acid concentration and cigarette smoking status Exhibit 13: Factors influencing the global gout therapeutics market 2015 Exhibit 14: Global gout therapeutics market snapshot: Developed and emerging markets 2015 Exhibit 15: Global gout therapeutics market 2015-2020 ($ billions) Exhibit 16: Opportunities in gout arthritis industry today Exhibit 17: Impact of drivers and challenges of global gout therapeutics market Exhibit 18: Five forces analysis Exhibit 19: Key buying criteria for gout therapeutics market Exhibit 20: Key buying criteria for global gout therapeutics market 2015 Exhibit 21: Impact of key customer segments on global gout therapeutics market 2015 Exhibit 22: Market segmentation by drug class: Global gout therapeutics market Exhibit 23: Common NSAIDs used for treatment of gout Exhibit 24: Market segmentation by drug class: Present and future scenarios Exhibit 25: Global gout therapeutics market: Segmentation by type 2015-2020 Exhibit 26: Global gout therapeutics market segmentation: Growth cycle analysis Exhibit 27: Snapshot of global gout therapeutics market by segmentation Exhibit 28: Snapshot of global gout therapeutics market by geography Exhibit 29: Global gout therapeutics market revenue by geography 2015-2020 ($ millions) Exhibit 30: Percentage share of global gout therapeutics market by geography 2015 Exhibit 31: Percentage share of global gout therapeutics market by geography 2020 Exhibit 32: Global gout therapeutics market: Country analysis based on revenue and growth rate Exhibit 33: Gout therapeutics market in Americas 2015-2020 ($ millions) Exhibit 34: Gout therapeutics market in EMEA 2015-2020 ($ millions) Exhibit 35: Opportunity of RDEA3170 in APAC Exhibit 36: Gout therapeutics market in APAC 2015-2020 ($ millions) Exhibit 37: Phase III clinical study data and future opportunities for urate-lowering agent - Zurampic (lesinurad) Exhibit 38: Impact of drivers Exhibit 39: Common CAM therapies used for gout treatment Exhibit 40: Usage of CAM therapies in US adults 2015 Exhibit 41: Impact of drivers and challenges Exhibit 42: Impact of trends on global gout therapeutics market Exhibit 43: Ranking of major vendors for global gout therapeutics market Exhibit 44: Geographical presence of key vendors Exhibit 45: Company portfolio analysis in global gout therapeutics market 2016-2020 Exhibit 46: AstraZeneca: Key highlights Exhibit 47: AstraZeneca: Strength assessment Exhibit 48: AstraZeneca: Strategy assessment Exhibit 49: AstraZeneca: Opportunity assessment Exhibit 50: Horizon Pharma: Key highlights Exhibit 51: Horizon Pharma: Strength assessment Exhibit 52: Horizon Pharma: Strategy assessment Exhibit 53: Horizon Pharma: Opportunity assessment Exhibit 54: Takeda Pharmaceuticals: Key highlights Exhibit 55: Takeda Pharmaceuticals: Strength assessment Exhibit 56: Takeda Pharmaceuticals: Strategy assessment Exhibit 57: Takeda Pharmaceuticals: Opportunity assessment

AstraZeneca, Horizon Pharma, Takeda Pharmaceuticals, Ablynx, Alder Biopharmaceuticals, Antares Pharma, Astellas Pharma, Boehringer Ingelheim, Can-Fite BioPharma, Celgene, Celltrion, ChemoCentryx, CymaBay Therapeutics, Eisai, Eli Lilly, Gilead Sciences, GlaxoSmithKline, Incyte, Ironwood Pharmaceuticals, JW Pharmaceutical, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, LG Life Sciences, Merck, Morphotek, Novartis, Novo Nordisk, Regeneron Pharmaceuticals, Sandoz, Sanofi, Santarus, Selecta Biosciences, Teijin Pharma, UCB, Vertex Pharmaceuticals.